What is Codexis's market cap?

Codexis (CDXS) has a market capitalization of $180.7M and trades on NASDAQ.

Who are Codexis's competitors?

Codexis's key competitors include Ginkgo Bioworks, Agilent Technologies, Maravai LifeSciences Holdings, Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.

Who does Codexis partner with?

Codexis's notable partners include GlaxoSmithKline, Merck & Co., Novartis, and others.

Where is Codexis headquartered?

Codexis is headquartered in United States of America and employs approximately 174 people. It has been publicly traded since 2010.

Codexis (CDXS) Stock Fundamentals & Financials

Codexis is a biotechnology company that develops high-performance enzymes and proteins to optimize the manufacturing of complex therapeutics.

Market cap

$180.68M-25.0%

Earnings

Q2 2026 report

August 11, 2026

Revenue$14.9MBeat by $1.1M EPS-$0.13Beat by $0.01

Read the full report

Next report

Nov 5, 2026 (in 2 months)

Revenue estimate$18.6M

EPS estimate-$0.09

Competitors

By market cap

Agilent Technologies$43.8B+29.9%

Illumina$34.0B+115%

Azenta$1.5B+6.2%

Maravai LifeSciences Holdings, Inc.$1.3B+293%

Editas Medicine$488.4M+103%

Ginkgo Bioworks$486.9M-33.4%

Codexis$180.7M-25.0%

Boundless Bio, Inc.$66.3M+160%

By revenue growth

Agilent Technologies+8.6%

Illumina+4.9%

Azenta+1.5%

Maravai LifeSciences Holdings, Inc.-5.0%

Ginkgo Bioworks-46.8%

By net margin

Agilent Technologies19.53%+1.6pp

Illumina18.36%-11.0pp

Azenta-20.02%-1.3pp

Maravai LifeSciences Holdings, Inc.-37.07%+50.5pp

Ginkgo Bioworks-259.96%-110pp

Profile

Codexis is a biotechnology company that develops high-performance enzymes and proteins to optimize the manufacturing of complex therapeutics. The company leverages its proprietary CodeEvolver directed evolution technology platform to engineer biocatalysts that improve purity, yield, and efficiency for pharmaceutical production. Its core value proposition lies in replacing traditional chemical synthesis with sustainable, aqueous-based enzymatic processes.

Competitive position

A pioneer in directed evolution and computational protein engineering with a dominant intellectual property portfolio in enzymatic RNA synthesis.

GeographiesUnited States, Europe, Global

Customer segmentsBiopharmaceutical companies, CDMOs, Research institutions

Business modelB2B, Licensing, Contract Development and Manufacturing (CDMO), Royalty-based

SuppliersThird-party contract manufacturing organizations (CMOs), Raw material suppliers for fermentation, Laboratory equipment providers

CustomersInnovator pharmaceutical companies, Generic drug manufacturers, Clinical-stage biotech firms, Diagnostic test developers

CountryUnited States of America

Listed2010

Employees174.0

CEOAlison Moore

SectorHealthcare

IndustryBiotechnology

Websitecodexis.com

FilingsSEC EDGAR

FAQ

What is Codexis's market cap?: Codexis (CDXS) has a market capitalization of $180.7M and trades on NASDAQ.
Who are Codexis's competitors?: Codexis's key competitors include Ginkgo Bioworks, Agilent Technologies, Maravai LifeSciences Holdings, Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.
Who does Codexis partner with?: Codexis's notable partners include GlaxoSmithKline, Merck & Co., Novartis, and others.
Where is Codexis headquartered?: Codexis is headquartered in United States of America and employs approximately 174 people. It has been publicly traded since 2010.